A recent study described that the antagonist GIP(3-30)NH2, when administered during an OGTT in patients with acromegaly, inhibited the paradoxical GH secretion in some patients, suggesting that targeting the GIP/GIPR axis could be a potential therapeutic approach for managing acromegaly in patients with GIPR-expressing pituitary adenomas [253]. Here, GH1 is linked to pituitary gland adenoma.